BUY SEMAGLUTIDE (2 MG/VIAL – 1 VIAL) ONLINE
Key product details:
- Active Ingredient: Semaglutide
- Strength: 2 mg per vial
- Molecular Formula: C187H291N45O59
- Molecular Weight: 4113.641 g/mol
- CAS Number: 910463-68-2
- Dosage Form: Lyophilised (freeze-dried) powder for reconstruction
- Route: Injection
- Product Pack: 1 vial
- Company: Hilma Biocare
- Market Status: Prescription
Main Product Description
Semaglutide 2 mg is a glucagon-like peptide-1 receptor agonist supplied as a lyophilised, freeze-dried powder for reconstruction. Semaglutide is a peptide medicine that acts on the GLP-1 receptor and influences several physiological processes involved in blood glucose regulation and appetite.
According to the supplied product information, semaglutide is used as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes. Higher-dose formulations are also described for long-term weight management in adults with obesity, or in adults who are overweight and have at least one weight-related comorbidity. Semaglutide is not indicated for people with type 1 diabetes according to the supplied information.
Semaglutide works by activating GLP-1 receptors. This mechanism increases insulin secretion when blood glucose is elevated, reduces glucagon secretion and slows gastric emptying. These effects can contribute to improved blood glucose control and changes in appetite and food intake.
The medicine also has an effect on appetite regulation. The supplied information states that semaglutide can reduce appetite and the amount of food a person wants to consume. It may also reduce preference for high-fat foods. These properties are relevant to its use in weight-management treatment when prescribed for an appropriate patient.
Clinical studies supplied with the product information describe additional effects on several cardiovascular and metabolic parameters, including plasma lipids and systolic blood pressure. The supplied information also mentions reductions in markers of inflammation. These observations should not be interpreted as a guarantee of cardiovascular or anti-inflammatory benefit for an individual patient.
Semaglutide has been investigated extensively for its effects on glucose metabolism and body weight. The supplied information mentions weight reduction in clinical use; however, individual responses vary considerably, and treatment outcomes depend on factors such as the patient’s medical condition, treatment plan, diet, physical activity and adherence to prescribed therapy.
Semaglutide 2 mg is presented as a freeze-dried powder requiring reconstruction before administration. Because this is a prescription injectable medicine, preparation, reconstitution, storage after preparation and administration should follow the product-specific instructions and the directions provided by a qualified healthcare professional. The supplied information does not provide sufficient details to establish a complete reconstitution procedure, so these details should not be inferred.
How Semaglutide Works
Semaglutide is a GLP-1 receptor agonist. GLP-1 is an endogenous hormone involved in the regulation of blood glucose and appetite. By activating GLP-1 receptors, semaglutide can:
- Increase glucose-dependent insulin secretion.
- Reduce glucagon secretion.
- Slow gastric emptying.
- Influence appetite and food intake.
- Support improved glycaemic control in appropriate patients.
- Contribute to weight reduction when prescribed for weight-management treatment.
The glucose-dependent nature of its insulin effect is an important part of its pharmacological activity. Semaglutide does not function as an anabolic steroid and should not be confused with conventional weight-loss stimulants or thyroid hormone medicines.
Clinical Uses
The supplied product information identifies two principal therapeutic areas for semaglutide.
Type 2 diabetes: Semaglutide may be prescribed alongside diet and exercise to improve glycaemic control in adults with type 2 diabetes.
Long-term weight management: Certain higher-dose formulations of semaglutide are indicated alongside diet and exercise for long-term weight management in adults with obesity or in adults who are overweight and have at least one weight-related health condition.
The appropriate formulation, strength and treatment plan depend on the individual patient and the authorised product being prescribed. Semaglutide should therefore be used according to professional medical advice rather than for unsupervised weight reduction.
Important Warnings
Semaglutide requires appropriate medical supervision. The supplied information advises patients to discuss their medical history with their doctor before treatment.
Particular attention should be given to a history of:
- Multiple endocrine neoplasia type 2 (MEN 2).
- Medullary thyroid carcinoma.
- Diabetic ketoacidosis.
- Pancreatitis.
- Kidney disease.
- Diabetic retinopathy or other diabetes-related eye problems.
Patients should also contact their healthcare professional if they experience symptoms such as a neck swelling or lump, difficulty swallowing, hoarseness or shortness of breath, as these symptoms require medical assessment.
Product Specifications
| Specification | Details |
|---|---|
| Product | Semaglutide |
| Strength | 2 mg/vial |
| Active Ingredient | Semaglutide |
| Molecular Formula | C187H291N45O59 |
| Molecular Weight | 4113.641 g/mol |
| CAS Number | 910463-68-2 |
| Dosage Form | Lyophilised powder for reconstruction |
| Route | Injection |
| Pack Size | 1 vial |
| Company | Hilma Biocare |
| Market Status | Prescription |
Storage and Handling
The supplied information identifies the product as a lyophilised powder for reconstruction. Storage and handling should therefore follow the manufacturer’s product-specific instructions and applicable pharmaceutical requirements. Do not assume storage conditions after reconstruction unless they are stated in the official product documentation.
As a prescription injectable medicine, Semaglutide 2 mg should be handled and administered only in accordance with appropriate professional instructions.
Important Information
Semaglutide is a prescription medicine and is not appropriate for everyone. It should not be presented as a guaranteed weight-loss treatment, and individual results can differ. The information above is based on the supplied product data and is intended as general product information rather than individual medical advice.
Before using semaglutide, patients should discuss their medical history, current medicines and treatment objectives with a qualified healthcare professional. Do not alter the prescribed treatment plan or use a different strength without professional guidance.
